LOS ANGELES, Feb. 28, 2018 -- Strategic Directions International (SDi), a division of BioInformatics Inc., today announced the release of the SDi Global Assessment Report 2018: The Laboratory Analytical & Life Science Instrumentation Industry. The 800+ page report details updated size, growth and market analyses for over 50 instruments in six major technology categories. In addition the projections, based on 15 editions over 20+ years of publication, are made on the industry’s prospects out to 2022 and include technology overviews, and detail market segment and regional developments. For this first time, users of the report will have an option to receive an electronic data stream updating the market projections on a quarterly basis.
“The overall analytical instrument industry is expected to grow by 4.6% reaching $71 billion by 2022,” said Mike Tice, Senior Vice President, Business Intelligence at SDi. “As the technology often on the leading edge of scientific research capabilities, mass spectrometry continues to have a bright future as the fastest-growing instrument segment and we project it will grow by almost 7%. Surface science techniques are also poised to make great gains buoyed by growing opportunities in life science applications.”
The SDi Global Assessment Report 2018: The Laboratory Analytical & Life Science Instrumentation Industry is the most trusted “gold standard” for measuring the size and growth of the analytical and life science instrumentation industry globally. A complimentary Executive Summary can be downloaded here. More information on the Global Datastream, which includes both the Global Assessment Report, and quarterly updates, can be found here. Additionally, users will receive the report in a PDF as well as an editable PowerPoint format.
The report covers 82 individual instrumentation and related technologies. Each technology is segmented according to several primary classifications typically related to underlying techniques. The six major sections updated this year include chromatography, life science instrumentation, mass spectrometry, molecular spectroscopy, atomic spectroscopy, and lab equipment. The remaining sections are updated every two years, and the surface science, materials characterization, lab automation, and general analytical techniques categories will contain an updated and extensive technology overview.
For each instrument and category, the report quantifies the regional distribution of demand; the size of the market segmented according to initial systems, aftermarket, and service; unit shipments/installations; growth rates; and demand by industry and lab function. Each section also explores the current state of the competitive playing field, including a list of the top vendors’ market shares, a vendor participation matrix, recent developments, and concludes with a short discussion that suggests where the market might be headed over the next five years from the related standpoints of technology, competition, and growth.
About SDi, BioInformatics Inc, and Instrument Business Outlook
Strategic Directions International (SDi), a leading international management-consulting firm in the highly specialized field of analytical instruments, was acquired by BioInformatics Inc in 2014. The two firms combined to form the premier research and advisory firm serving the life science and analytical instrument industry. By leveraging our verified online professional network of tens of thousands of scientists in The Science Advisory Board®, we have supported more than 500 companies and provided insights that lead to better business decisions. Our expertise includes assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customers’ brand loyalty, and evaluating brand strength and positioning, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning. SDi and BioInformatics Inc are supported by their own bi-weekly online publication Instrument Business Outlook.
www.gene2drug.com
For more information contact: Mike Tice Senior Vice President of Business Intelligence Strategic Directions International A division of BioInformatics Inc. 6242 Westchester Parkway, Suite 100 Los Angeles, CA 90045-4820 United States Phone: 310.641.4982 [email protected]


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Washington Post Publisher Will Lewis Steps Down After Layoffs
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Instagram Outage Disrupts Thousands of U.S. Users
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



